Newsroom

October 2019

• Ad hoc release Oct 22, 2019

  Novartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von Beovu

  Der Nettoumsatz der fortzuführenden Geschäftsbereiche2 steigt aufgrund folgender Beiträge um 13% (kWk1, +10% USD): Cosentyx erzielt einen Umsatz von USD 937 Millionen (+27% kWk)…
• Ad hoc release Oct 22, 2019

  Novartis, encore un fort trimestre: croissance à deux chiffres des ventes et expansion de la marge core1; hausse des prévisions de chiffre d’affaires et de résultat en 2019; Beovu lancé aux USA

  Chiffre d’affaires net des activités poursuivies2 en hausse de 13% (tcc1, +10% USD) soutenu par: Cosentyx: USD 937 millions (+27% tcc), avec une forte demande dans toutes les indications et…
• Press release Oct 16, 2019

  Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease

  REACH2 trial results confirm Jakavi significantly improves overall response rate (ORR) at 28 days vs. best available therapy in steroid-refractory acute graft-versus-host disease (GvHD)[1] GvHD…
• Featured News Oct 11, 2019

  Pride @ Novartis 2019

  As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.
• Press release Oct 10, 2019

  Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis

  New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
• Featured News Oct 10, 2019

  World Sight Day 2019
• Press release Oct 09, 2019

  Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice

  Data from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical…
• 
  Story Oct 08, 2019 Patient Perspectives

  Lessons from a blind chef

  Christine Hà lost her vision at a young age – and went on to become an award-winning chef.
• Press release Oct 08, 2019

  Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg

  Results from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
• Ad hoc release Oct 08, 2019

  Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

   In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
• 
  Story Oct 07, 2019 People and Culture

  Oncology Careers: Life Changing Purpose
• Press release Oct 05, 2019

  AveXis presents updated STRONG data at WMS

  Older patients (≥ 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up…